Category Archives: Strategy
By Pharm Exec | Published: September 16, 2014
Merck’s Keytruda, recently approved in the US to treat patients with advanced melanoma that have stopped responding to other cancer therapies, will soon face strong competition from Bristol-Myers Squibb’s (BMS) Opdivo, an analyst from research and consulting firm GlobalData has reported.
By Guest Blogger | Published: September 11, 2014
The role of medical affairs is taking on greater importance, as relationships between life sciences companies and external stakeholders become more complicated. Medical affairs is required to communicate more often with medical practitioners, scientific researchers, patients, patient advocates, and government authorities, and to provide these groups with more complex and more comprehensive information. Unfortunately, many […]
By William Looney | Published: September 11, 2014
Pharm Exec‘s 13th Industry Audit looks at how well a cross section of companies in big Pharma, mid-tier specialty and biotech are delivering against today’s hottest performance metric: shareholder value. When we began the series back in September 2002, this kind of broad indicator—indeed the very concept of “value”—was often discounted by the investment community in […]
By Pharm Exec | Published: September 11, 2014
In this special Technology Issue of Pharm Exec Global Digest: Apple or Big Pharma: Who Will Lead in the Wearable Healthcare Device Space?; Google Glass — a Healthcare User’s Guide; UBISTART’s New Payout for Innovative Start-ups; and more… Click here to read the issue.
By Pharm Exec | Published: September 5, 2014
David Schlanger became WebMD’s CEO in August of 2013, but first joined the company in 1995, after serving as executive director, business development at Merck. The commercialization of pharmaceutical drugs has changed a lot in two decades: industry’s focus on specialty drugs for smaller populations and patients with chronic disease has supplanted the emphasis on […]